已核实 DOI PubMed 相关产品: 19

Glucose-primed PEEK orthopedic implants for antibacterial therapy and safeguarding diabetic osseointegration

Journal 2023 · IF 14 · 发表于 2023 年 11 月 4 日
作者: Miaomiao He,Hao Wang,Qiuyang Han,Xiuyuan Shi,Shuai He,Jiyu Sun,Zhuoli Zhu,Xueqi Gan,Yi Deng
阅读全文 在 PubMed 查看

摘要

Diabetic infectious microenvironment (DIME) frequently leads to a critical failure of osseointegration by virtue of its main peculiarities including typical hyperglycemia and pathogenic infection around implants. To address the plaguing issue, we devise a glucose-primed orthopedic implant composed of polyetheretherketone (PEEK), Cu-chelated metal-polyphenol network (hauberk coating) and glucose oxidase (GOx) for boosting diabetic osseointegration. Upon DIME, GOx on implants sostenuto consumes glucose to generate H 2 O 2 , and Cu liberated from hauberk coating catalyzes the H 2 O 2 to highly germicidal •OH, which massacres pathogenic bacteria through photo-augmented chemodynamic therapy. Intriguingly, the catalytic efficiency of the coating gets greatly improved with the turnover number (TON) of 0.284 s −1 . Moreover, the engineered implants exhibit satisfactory cytocompatibility and facilitate osteogenicity due to the presence of Cu and osteopromotive polydopamine coating. RNA-seq analysis reveals that the implants enable to combat infections and suppress pro-inflammatory phenotype (M1). Besides, in vivo evaluations utilizing infected diabetic rat bone defect models at week 4 and 8 authenticate that the engineered implants considerably elevate osseointegration through pathogen elimination, inflammation dampening and osteogenesis promotion. Altogether, our present study puts forward a conceptually new tactic that arms orthopedic implants with glucose-primed antibacterial and osteogenic capacities for intractable diabetic osseointegration.

本研究中使用的阿拉丁产品

19 款产品在本文中被引用